The present invention relates to a Nudix5 inhibitor for use in the treatment and/or prevention of cancer in a subject and pharmaceutical compositions comprising a therapeutically effective amount of a Nudix5 inhibitor and a pharmaceutically acceptable excipient or carrier, and to a pharmaceutical composition comprising a therapeutically effective amount of a composition comprising a Nudix5 inhibitor and at least a second antitumor agent and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for assaying the activity of Nudix5 comprising assaying the formation of ATP, and to a method for identifying a compound potentially useful for treating and/or preventing cancer comprising assaying the activity of Nudix5 in the presence of said compound.
本发明涉及一种用于治疗和/或预防受试者癌症的Nudix5抑制剂和药物组合物,该药物组合物包含治疗有效量的Nudix5抑制剂和药学上可接受的赋形剂或载体,还涉及一种药物组合物,该药物组合物包含治疗有效量的组合物,该组合物包含Nudix5抑制剂和至少第二种抗肿瘤剂以及药学上可接受的赋形剂或载体。此外,本发明还涉及一种检测 Nudix5 活性的方法,该方法包括检测 ATP 的形成;本发明还涉及一种鉴定可能用于治疗和/或预防癌症的化合物的方法,该方法包括在所述化合物存在的情况下检测 Nudix5 的活性。
Schmidt; Schach, Justus Liebigs Annalen der Chemie, 1951, vol. 571, p. 29,34